Mass drug administration (MDA), a strategy in which all individuals in a population are subject to treatment without individual diagnosis, has been recommended by the World Health Organization for controlling and eliminating several neglected tropical diseases, including trachoma and soil-transmitted helminths. In this paper, we derive effective reproduction numbers and average post-treatment disease prevalences of a simple SIS (susceptible-infectious-susceptible) epidemic model with constant, impulsive synchronized, and non-synchronized drug administration strategies. In the non-synchronized model, the individuals in the population are treated at most once per period and their treatment times are uniformly distributed. Mathematically, the set of pulses for the non-synchronized model has the cardinality of the continuum. We show that synchronized and constant strategies are respectively the most and least effective treatments in disease control. Elimination through synchronized treatment is always possible when adequate drug efficacy and coverage is fulfilled and sustained. For a strategy with multiple rounds of synchronized treatment per period, the average post-treatment prevalence is irrelevant what the time differences between treatments are, as long as there are the same number of treatments per period.
Introduction
Mass drug administration (MDA) is the distribution of drugs to entire populations, regardless of ascertainment of disease or infection status. It was once widely implemented in the era of malaria eradication campaign with generally unsuccessful outcome, due to emerging drug and insecticide resistance. We 2 of 19 D. GAO ET AL. ask the following questions: is it feasible to eliminate infection with repeat mass treatments, what is the minimum necessary frequency of mass treatment for a given population or geographic region, how can we maximize cost-effectiveness with limited resources, and finally, when can MDA be terminated (Ray et al., 2009 )? Melese et al. (2004 Melese et al. ( , 2008 conducted randomized clinical trials in the Gurage Zone in Ethiopia and their studies strongly suggests the feasibility of locally eliminating trachoma with repeat mass antibiotic distributions.
Repeat mass treatment may be studied using the theory of impulsive systems as a useful idealization. The transmission dynamics of infectious diseases undergoing impulse effects can be described by a system of impulsive differential equations (Lakshmikantham et al., 1989; Bainov & Simeonov, 1993) , i.e., continuous-time differential equations between impulses and impulsive equations at the time of impulse. The main difference between impulsive and periodic epidemic models is that the former describe instantaneous changes in the values of state variables at impulsive points, while the latter describe periodic changes in the values of model parameters (Bacaër & Ouifki, 2007; . For example, there are numerous studies on disease control and elimination in the presence of pulse vaccination (Agur et al., 1993; Shulgin et al., 1998; Gao et al., 2007; Yang et al., 2013) , pulse chemotherapy (Panetta, 1996; Lakmeche & Arino, 2000; Smith, 2006) , pulse radiotherapy (Freedman & Belostotski, 2009) , pulse immunotherapy (Bunimovich-Mendrazitsky et al., 2008; Castiglione & Piccoli, 2007) , pulse removal (Fuhrman et al., 2004; Jin & Haque, 2007) , and pulse birth (Roberts & Kao, 1998; Jiang & Yang, 2009) .
MDA, however, differs from vaccination in that it helps infected people to recover from illness, infection, or colonization, while vaccines are usually used to help uninfected people develop temporary or lifelong immunity. A theory of disease elimination by mass drug administration is being developed (Anderson et al., 2012) . By fitting a stochastic model to observed data for trachoma, Lietman et al. (1999) concluded that moderate endemic areas need annual MDA in eliminating trachoma, while hyperendemic areas need biannual MDA. Ray et al. (2007) fitted a stochastic epidemic model to collected data from Ethiopia and found that local elimination is achievable, while large-scale elimination requires more frequent treatments and the reduction of imported transmission. Based on a periodic Ross-Macdonald model, numerically found that the optimal timing of mass drug administration for malaria is not at high mosquito season. Griffin and his collaborators (2010, 2015) studied the effect of pulsed interventions (such as mass drug administration and indoor residual spraying) on the reproduction number for malaria with seasonally varying mosquito numbers.
In this paper, we will use mass oral azithromycin administration for trachoma as a case study. Trachoma is an infectious ocular disease caused by the bacterium Chlamydia trachomatis and it has long been a leading cause of blindness and visual impairment. About 232 million people in 51 countries are at risk of trachoma worldwide, of whom approximately 55 million people received antibiotic treatments for trachoma in 2013. Repeated administration of antibiotics has dramatically reduced the prevalence of active trachoma in many areas (Schachter et al., 1999; Gaynor et al., 2003; Burton et al., 2010) . A single-dose of the macrolide antibiotic azithromycin takes less than a week to clear Chlamydia trachomatis with an average efficacy of 92-98% and the WHO recommended coverage for trachoma control programs is 80% or higher (Lietman et al., 1999) . There is no documented evidence of emerging azithromycin resistance after mass distribution of azithromycin for trachoma (Solomon et al., 2005; Hong et al., 2009) .
Trachoma campaigns are typically conducted by having teams of field workers visit communities and apply antibiotics to everyone at the same time. While expensive, this reduces the possibility of creating a temporal refuge for the bacterium in individuals who are not treated at a particular time. But we may, however, consider an alternative strategy, in which mass administration is transferred to routine care, each child receiving his or her annual dose at (for instance) a birthday, avoiding the need for 3 of 19 centrally coordinated field teams. Are asynchronous or decentralized MDA campaigns feasible? In what follows, we will explore idealized models to gain insight into the importance of synchrony in application of MDA, by examining models in which individuals are treated annually, but asynchronously.
In the next section, we consider three formulations of a deterministic SIS (susceptible-infectioussusceptible) epidemic model under: (1) constant treatment, (2) impulsive synchronized treatment (representing what might be seen in practice), and (3) a hypothetical non-synchronized treatment campaign, respectively. In the constant treatment model, antibiotics are constantly distributed to a population at random and an individual may receive multiple doses in one treatment period. In both the impulsive synchronized and non-synchronized treatment models, no one receives more than one dose in one treatment period; for example, for annual mass treatment, no one receives more than one dose per year. The synchronized model represents the typical mass drug administration where the whole population receives treatment nearly at the same time. In the non-synchronized model, each individual is still only treated once per period, but the individuals in the population are treated at different times, distributed uniformly throughout the time period. The effective reproduction numbers and average disease prevalences of the model under all three drug administration strategies are derived and compared in section 3. Numerical examples are presented to confirm theoretical results and to determine right treatment frequency for regions with different levels of endemicity or disease intensity in section 4.
Three treatment strategies
We consider a simple SIS infectious process with standard incidence, in which infection confers shortterm immunity or none at all to an infectious individual upon recovery. For a constant population, let S(t) and I(t) be the fractions of uninfected and infected people at time t, respectively. The disease transmission is described by a system of two ordinary differential equations
where β is the transmission coefficient and γ is the recovery rate. It is well-known that the basic reproduction number of the model (2.1) is R 0 = β /γ and the disease dies out for stochastic effects if R 0 1 and persists at an endemic equilibrium Brauer & Castillo-Chavez, 2012) . The antibiotic efficacy depends not only on effective coverage but also on drug distribution strategies. A strategic distribution plan to maximize the effectiveness of antibiotics and minimize the risk of side effects is most desirable. This is particularly crucial in areas where health care resources are very limited or antibiotic resistance is a big concern. In what follows, we will compare three typical drug distribution strategies (regardless of health status): constant treatment, impulsive synchronized MDA, and impulsive non-synchronized treatment. Let T be the length of one treatment period (e.g., one year), p be the curative efficacy, q be the coverage rate, and θ = p × q ∈ (0, 1) be the effective coverage of a single distribution (further details will be provided below). The medication is assumed to take effect instantaneously at dosing time and does not drive significant antibiotic resistance. In Table 1 , we give a summary of parameter descriptions and ranges based on trachoma. 
Constant treatment
The treatment is modeled as a continuous process in which individuals receive treatment at rate θ /T . The fraction of infected population follows the equation
The effective reproduction number of model (2.2) is R c = β γ+θ /T , the disease eventually disappears if R c 1, and the disease prevalence stabilizes at
In this model, for example, we may consider each individual to receive treatments according to a Poisson process with intensity given by θ /T , so that some individuals receive more than one treatment per period, while others receive none.
Impulsive synchronized treatment
Assuming that drugs are distributed to the whole population at the same time with effective coverage θ (i.e., the fraction of people being successfully treated) and the effects of drugs are instantaneous. The proportion of the population who are infectious satisfies
3) where δ (t) is the Dirac delta function (i.e., 1 when t = 0 and 0 otherwise). We define the effective reproduction number of model (2.3) as R 1 = β γ−ln(1−θ )/T (see e.g., Melese et al., 2004 ). More generally, consider a treatment strategy with multiple rounds of impulsive synchronized MDA per period where the change in infectives is described by
We assume that 0
, and θ k+m = θ k for k = 0, 1, . . . , and m ∈ {1, 2, . . . }. Clearly, (2.4) is a logistic system with periodic impulsive perturbations and its effective reproduction number is defined as
(see Jin & Haque, 2007; Liu & Chen, 2004) . If R m,1 > 1 then (2.4) possesses a unique positive periodic solution, denoted by I * (t), which is globally attractive (Liu & Chen, 2004 ).
Impulsive non-synchronized treatment
In reality, individuals are not, in fact, simultaneously treated. We also, therefore, consider the opposite special case: each individual receives no more than one treatment per period and the distribution of treatment times in the entire population is uniform over the treatment period. Specifically, the nonsynchronized model divides one treatment period into infinitesimal intervals (t,t + ∆t), to each of which there corresponds a small fraction of the population, ∆ H, who are treated at times t,t +T,t +2T, . . . , over time. In other words, we split a completely homogeneous population and one treatment period into the same number of portions satisfying n ≡ 1/∆ H = T /∆ T ; and periodically treat the j-th subpopulation of
. . , for j=1,. . . ,n. All subpopulations are well-mixed and each of them is subject to the same force of infection determined by the overall instantaneous prevalence, I(t). The fraction of the infectives in the j-th subpopulation, denoted by I j (t), satisfies
where
) is formed by a cooperative system with a recurrent pulse effect. As the number of portions, n, increases to infinity, we obtain a limiting system of (2.5). Let s(a,t) and i(a,t) be the densities of the uninfected and infected at phase a ∈ [0, T ) and time t, respectively, s(a,t)∆ a and i(a,t)∆ a be the fraction of uninfected and infected people at phase interval [a, a + ∆ a) and time t, respectively. Obviously, we have s(a,t) + i(a,t) = 1, for ∀a ∈ [0, T ) and t 0.
The overall fraction of infectives in the population at time t is I(t) =
with initial condition satisfying 0 < I(0) 1 and 0 i(a, 0) 1 for a ∈ [0, T ). Note that system (2.6) has a continuum (ℵ 1 ) of pulses; this differs from the typical impulsive differential equation model in which the number of pulses is countably infinite.
Mathematical results
In this section, we first solve the impulsive synchronized model (2.3) and obtain its average prevalence at the stable state if the disease remains persistent after repeat treatments. Then we study the impulsive non-synchronized treatment model (2.6) and establish the global threshold dynamics in terms of the effective reproduction number. Finally, we compare the three treatment strategies through their corresponding effective reproduction numbers, stable average prevalences and other measures. By a change of variables: β T → β , γT → γ and t/T → t, it suffices to consider the models (2.2)-(2.6) with T = 1.
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The solution of the impulsive synchronized model
Solving the logistic differential equation
by separating variables, we obtain
The average prevalence of the synchronized model (2.3) at the positive stable state is
We can derive the stable average prevalence of the m rounds of impulsive synchronized MDA model (2.4), denoted by P m,1 , without solving the model equation. If R m,1 > 1 then the unique positive periodic solution (S * (t), I * (t)) of (2.4) exists and satisfies For an example of biannual treatment strategy, the post-treatment prevalence is independent of the time difference between two biannual treatments as long as they are twice per year.
The solution of the non-synchronized model
It follows from theoretical studies on impulsive cooperative systems (Liu & Chen, 2006; Jiang, 1994) and numerical simulations (see Fig. 1 ) of the discretized system (2.5) that the disease under nonsynchronized treatment either dies out or persists at a positive periodic state, denoted by (I * 1 (t), . . . , I * n (t)). Moreover, the periodic solution satisfies I * j (t + 1) = I * j (t) and I * j (t) = I * j+1 (t + 1/n) for 1 j n − 1. The overall instantaneous prevalence I * (t) = ∑ n j=1 I * j (t) is a 1/n-periodic function. In fact, As the partition of population and time gets finer and finer, the period of the overall prevalence function I * (t) of (2.5), 1/n, becomes smaller and smaller and I * (t) approaches a constant as n → ∞. Hence the solution of the limiting system (2.6) either converges to zero or a time-periodic state, denoted by i * (a,t) . Similarly, the time-periodic solution satisfies i * (a,t + 1) = i * (a,t) and i * (a,t) = i * (a + s,t + s), t 0, In fact, equalities (3.1) and the change of variables give
We next establish the necessary and sufficient conditions for the disease persistence of the nonsynchronized model (2.6) and estimate the stable average prevalence P ∞ ≡ I * (t) = I * (0) or I * 0 . It follows from (3.1) that it suffices to solve the linear impulsive differential equation
at t ∈ (0, 1]. Direct calculations find that (3.2) has a unique globally stable periodic solution
Making the substitution (3.3) in above equation yields
which is a complex transcendental equation of I * 0 . Before proceeding further, we present a lemma which is useful in later proofs and whose proof is postponed to Appendix A. 
Moreover, the condition F ′ (0) > 0 is also necessary for the existence and uniqueness of a positive zero of F(I). The proof can be found in Appendix B. Now we define the effective reproduction number of the impulsive non-synchronized treatment model (2.6) as
The model (2.6) also demonstrates global threshold dynamics which are determined by the reproduction number.
THEOREM 3.2 For model (2.6), assume that there always exists a globally stable solution. If R ∞ 1 then the disease goes extinct; else if R ∞ > 1 (implies R 0 > 1) then there is a time-periodic positive solution i * (a,t) which is globally asymptotically stable, and the overall disease prevalence I(t) converges to P ∞ ≡ I * 0 provided that the disease is initially present. Here I * 0 = (Y * − γ)/β and Y * is the unique positive zero of the function
The proof of Lemma 3.2 indicates that F ′ (0) and G(γ) have the same sign, and G(γ) > 0 if and only if R ∞ > 1. The above theorem is immediately followed by Lemma 3.2.
Comparison of the reproduction numbers and prevalences
We now determine the best treatment strategy through the comparison of their effective reproduction numbers, post-treatment prevalences, minimum required effective coverage rates and maximum allowable periods for elimination. Recall that R c = β /(γ + θ ) and R 1 = β /(γ − ln(1 − θ )). In the following, we ignore the trivial case where the disease will eventually go extinct with or without treatment. PROPOSITION 3.1 For any given parameter set, we have R c > R ∞ > R 1 and P c > P ∞ > P 1 .
Proof. It follows from h(γ) ∈ (0, 1/2) and g(θ ) ∈ (1/2, 1) for γ > 0 and θ ∈ (0, 1) that
On the other hand, if R ∞ > 1 then
and
We conclude that G(β P c + γ) < 0 = G(β P ∞ + γ) < G(β P 1 + γ) and hence P c > P ∞ > P 1 . REMARK 3.2 Note that P c = 1 − 1/R c and P 1 = 1 − 1/R 1 . However, P ∞ > 1 − 1/R ∞ > P 1 . Actually, by the strict monotonicity of h(x) on [0, ∞), we know that
For a general value of the treatment cycle T , the minimum required effective coverage θ min for elimination of infection using constant treatment, impulsive synchronized MDA, and impulsive nonsynchronized treatment, if it exists, are
, respectively, provided that R 0 = β /γ > 1. For any given effective coverage θ ∈ (0, 1), the maximum allowable period T max of constant treatment, impulsive synchronized MDA, and impulsive nonsynchronized treatment for elimination of infection are
respectively, provided that R 0 = β /γ > 1. Here T ∞ > 0 is the unique zero of the strictly increasing functionĜ
It follows from Lemma 3.1 that
Hence θ c > θ ∞ > θ 1 and T c < T ∞ < T 1 , so that impulsive synchronized MDA uses the least antibiotic to achieve elimination. For any given transmission setting and treatment cycle, the impulsive synchronized MDA is always able to eradicate the disease with sufficiently high effective coverage, while the other two treatment strategies may fail. In addition, if we equally split one pulse into m pulses at time kT, kT + T /m, . . . , kT + T (m − 1)/m, then the corresponding effective reproduction number and stable average prevalence for impulsive synchronized MDA and impulsive non-synchronized treatment are
respectively, where P ∞, m is the unique positive root of the equation
As expected, both R 1, m and R ∞, m are strictly increasing to R c as m → ∞. By the squeeze theorem, P 1, m and P ∞, m converge to P c as m → ∞. 
The main results we obtained in this paper are summarized in Table 2 . 
Numerical simulations
In this section, using trachoma as a case study, we give examples to compare the maximum allowable period for elimination, minimum required effective coverage, the speed of convergence of three treatment strategies. We discuss the situations when trachoma can be administrated by a single dose of azithromycin on an annual or biannual basis. Unless stated otherwise, time is measured in years in what follows.
EXAMPLE 4.1 Choose β = 1.8 and γ = 0.9. Using formula (3.4), the relationship between T max and θ under three treatment strategies are plotted in Fig. 2a . With 90% effective coverage, the maximum allowable period of impulsive synchronized MDA is 2.6-fold longer than that of constant treatment.
When individuals are treated annually, Fig. 2b describes the average prevalence at the stable state of each treatment strategy versus effective coverage. The minimum effective coverage requirements are θ c = 90%, θ 1 = 59.3% and θ ∞ = 65.1%, and the impulsive synchronized MDA is most effective. Moreover, the impulsive synchronized MDA takes less time to achieve elimination than either constant or impulsive non-synchronized treatment does (see Fig. 3a ). However, if the impulsive synchronized MDA cannot eliminate infections, then it may take longer time to stabilize at a stable periodic state than others do (see Fig. 3b ). EXAMPLE 4.2 With parameter ranges in Table 1 , we use the Latin hypercube sampling method to generate 100,000 parameter sets of the form {β , γ, θ }. Since the goal of the WHO trachoma control program is to reduce active trachoma to less than 5% in children aged 1-9 years (Melese et al., 2004; Taylor et al., 2014) , and impulsive synchronized MDA may be discontinued if the trachoma prevalence falls below the set threshold, we choose 45,418 scenarios whose equilibrium prevalences before treatment are greater than 5%. Among these qualified scenarios, 15,919 have pretreatment prevalence less than 35%, 7,929 have pretreatment prevalence from 35%∼50%, the remaining 21,570 have pretreatment prevalence greater than 50%. The maximum allowable treatment periods of all qualified scenarios (black solid line) and scenarios with pretreatment prevalence less than 35% (blue dash-doted line), from 35% to 50% (yellow dashed line), and greater than 50% (red dotted line), are presented in Fig. 4 . In particular, 85.6% of simulations that start with less than 35% pretreatment prevalence, representing low to moderately endemic areas, end in elimination with annual mass treatment, while 43.9% simulations that start with over 50% pretreatment prevalence, representing hyperendemic areas, cannot eliminate infections with biannual treatment. It somewhat differs from previous work (Lietman et al., 1999) , because we used broader parameter ranges. These numerical results provide a quantitative exploration of the impulsive synchronized model, but direct applicability to any particular setting would require detailed parameter fitting based on prevalence surveys. Table 1 .
In addition, based on qualified scenarios, the partial rank correlation coefficients for maximum allowable treat period with respect to β , γ and θ are −0.83, 0.82 and 0.73, respectively. This suggests that all three parameters are almost equally important in determining T 1 .
Discussion
Mass drug administration, i.e. the treatment of all at-risk populations without assessment of infection, is being implemented as a core strategy for the control and elimination of several neglected tropical diseases around the globe. The success of MDA programs depends on the treatment coverage and efficacy of the drugs, as well as the costs, side effects, and drug resistance. In this paper we use a simple SIS model to determine the feasibility of disease elimination via synchronized MDA and compare it with constant treatment and impulsive non-synchronized treatment. In terms of post-treatment prevalence, synchronized MDA is far more effective than impulsive non-synchronized treatment, while impulsive non-synchronized treatment is slightly better than constant treatment (P c > P ∞ > P 1 ). MDA as currently implemented is substantially better than non-synchronized alternatives. For a given treatment frequency (i.e., times per year), elimination by synchronized MDA is always possible with appropriate effective coverage, while the other two treatment strategies may fail (R c > R ∞ > R 1 ). Our analysis of the maximum allowable period and minimum required effective coverage may provide guidance in specific settings on the appropriate treatment frequency and coverage. The idea behind the nonsynchronous model is applicable to other impulsive non-synchronized processes such as periodic mass immunization program. This model could, for instance, be extended to assess the consequences of year round field teams visiting each region once per year (for instance), but visiting each region at a different time.
For the treatment strategy with multiple rounds of synchronized MDA per period, we note that the average prevalence only depends on the number of rounds, but not on their timing within the period. However, the timing of MDA does matter if seasonal effects are considered (Lee et al., 2005) . Numerical calculations suggest that the selection of treatment times does make a difference for the discretized model (2.5). We conjecture that the impulsive non-synchronized treatment is the least effective periodic unrepeated treatment strategy.
We note that MDA has considerably broader application than trachoma. It has been successfully used for malaria and lymphatic filariasis in China and onchocerciasis in Latin America. MDA can be used to contain and eliminate an infectious disease if inexpensive, safe and highly effective medicines are available (Hotez, 2009; Smits, 2009 ). The World Health Organization (WHO) recommends repeat use of albendazole with ivermectin or diethylcarbamazine for lymphatic filariasis, ivermectin for onchocerciasis, praziquantel for schistosomiasis, albendazole or mebendazole for soiltransmitted helminths, and azithromycin for trachoma (Hotez, 2009; Smits, 2009) . About 711 million people received MDA treatments in 2010 and more than 1.9 billion people in 124 countries require annual MDA for at least one neglected tropical disease (NTD) (World Health Organization, 2013) . Note that Anderson et al. (2014) and Truscott et al. (2014a Truscott et al. ( , 2014b ) studied the possibility for control and elimination of soil-transmitted helminths through repeated mass treatment programs. The 2012 London Declaration on NTDs aims to eliminate or control 10 of the 17 NTDs by 2020. Extensions of the model we presented for trachoma could be used to examine alternative implementations of MDA-based control in such macroparasitic settings.
The current study provides insight into the important role of synchrony in the implementation of MDA. More comprehensive studies should consider the influence of partial acquired immunity (Liu et al., 2013) , chemoprophylaxis in susceptible persons, seasonality in transmission (Lee et al., 2005) , age-structure in the host population Lietman et al., 1999 , Gambhir et al., 2009 ), bacterial load (Shattock et al., 2015) , case importation, and other ecological or epidemiological factors (Lietman et al., 1999) . Changes in population size, structure and distribution need to be reflected in a long term MDA program. In clinical trials, antibiotic treatment may only target those at the highest risk of infection (e.g., people with symptoms, or those under a certain age (Lietman et al., 1999) , known as targeted mass drug administration (TMDA), which is similar to targeted mass vaccination (Keeling & Rohani, 2008) . A large-scale MDA campaign involving millions of people takes neither a day nor a full period, so a more general model based on the non-synchronized model and the non-treatment model may be more realistic. In the presence of antibiotic resistance, a strategy to reach the goal of elimination and to reduce the risk of emerging resistance associated repeat treatments is expected. In cases where the efficacy of oral azithromycin for trachoma is lower than previously estimated , more repeated distributions per period are required for elimination. A combination of MDA and other interventions (e.g., the SAFE strategy for trachoma -Surgery, Antibiotics, Facial cleanliness and Environmental improvement) could interrupt disease transmission more rapidly and reduce the use of antibiotics.
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